Five Prime Therapeutics and Zai Lab start Phase 3 study of bemarituzumab for advanced gastric cancer

California-based Five Prime Therapeutics and Chinese biopharma Zai Lab have initiated a pivotal Phase 3 trial of bemarituzumab (FPA144) in combination with chemotherapy for patients ... Read More